Results 61 to 70 of about 250,617 (262)

Identifying transcription factors controlling the basal expression of human MRP4 highlights a substantial role for Sp1

FEBS Open Bio, EarlyView.
The MRP4 transporter exports several drugs and signaling molecules. Here, we identified key promoter elements regulating basal MRP4 expression. Using reporter assays, we defined a conserved region with essential Sp1 and contributory Ets sites, which controlled basal MRP4 expression.
Debora Singer, Angelique Kragl, Katrin Ziems, Juliane Glaubitz, Sophie Grammbauer, Susanne Hildebrandt, Mladen V. Tzvetkov, Gabriele Jedlitschky   +7 more
wiley   +1 more source

Time‐restricted feeding prior to Mycobacterium tuberculosis infection reduces tissue CD4+ T cells with limited impact on bacterial clearance

FEBS Open Bio, EarlyView.
Time‐restricted feeding (TRF) in mice increased liver fatty acid oxidation and decreased fatty acid biosynthesis. These alterations persisted when TRF was discontinued and the host was infected with Mycobacterium tuberculosis. Pre‐exposure to TRF did not alter tissue (lung and spleen) mycobacterial burden but significantly reduced CD3+ T cells in lungs
Ashish Gupta, Nidhi Yadav, Subhasmita Das, R. Rajendra Kumar Reddy, Nupur Sharma, Amol Ratnakar Suryawanshi, Jaswinder Singh Maras, Ranjan Kumar Nanda   +7 more
wiley   +1 more source

The CAR T Cell Story

healthbook TIMES. Oncology Hematology, 2019
During the entire 20^th^ century, chemotherapy and irradiation were the mainstay of non-surgical cancer treatment. In the past 20 years, however, cancer immunotherapy has been revolutionizing the field of oncology with ever-increasing pace.
Norman Russkamp, Thorsten Zenz
doaj   +1 more source

Small RNA pathways in mammalian oocytes

FEBS Open Bio, EarlyView.
Three distinct small RNA pathways operate in mammalian oocytes: RNAi interference (RNAi), the microRNA (miRNA) pathway, and the PIWI‐associated RNA (piRNA) pathway. These pathways use small RNAs to guide sequence‐specific repression and contribute to oocyte biology by targeting genes and mobile elements or appear insignificant since different ...
Petr Svoboda, Josef Pasulka
wiley   +1 more source

Safe CAR-T: shedding light on CAR-related T-cell malignancies

EMBO Molecular Medicine
As of September 30, 2023, the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database has received 12 reports of secondary T-cell malignancies since the first of the BCMA-/CD19-targeted autologous CAR-T therapies was approved ...
Qibin Liao, Jianqing Xu
doaj   +1 more source

Nephrotoxicity in CAR-T Cell Therapy

Transplantation and Cellular Therapy
Chimeric antigen receptor (CAR)-T cell therapy is a novel therapy for the treatment of different hematologic malignancies. Besides its efficiency, CAR-T cell therapy is associated with significant toxicity, primarily manifested as cytokine release syndrome (CRS) and neurotoxicity.
Karol Sadowski, Weronika Ploch, Alicja Downar, Wiktoria Giza, Dorota Szcześ, Wioletta Olejarz, Wiesław W. Jędrzejczak, Jolanta Małyszko, Grzegorz Basak   +8 more
openaire   +2 more sources

Effects of IGFBP4 deficiency on human preadipocyte proliferation and differentiation through the IGF1R/AKT pathway

FEBS Open Bio, EarlyView.
IGFBP4 knockdown (KD) impairs preadipocyte proliferation and is associated with IGF1R protein downregulation and attenuated AKT phosphorylation. The mechanisms by which IGFBP4 KD influences the IGF1R/AKT signaling pathway involve newly synthesized proteins and lysosomal degradation pathways. Created in BioRender.
Yujia Guo, Sandy Richter, Christoph Bach, Wieland Kiess, Anna Kirstein, Diana Le Duc, Antje Garten   +6 more
wiley   +1 more source

XCL1-secreting CEA CAR-T cells enhance endogenous CD8+ T cell responses to tumor neoantigens to confer a long-term antitumor immunity

Journal for ImmunoTherapy of Cancer
Background Therapeutic efficacy of carcinoembryonic antigen (CEA)-specific chimeric antigen receptor (CAR) T cells against colorectal cancer (CRC) remains limited due to the unique characteristics and distinct microenvironments of tumor tissues.
Kun Chen, Fei Zhao, Hong Zhao, Dongmei Wang, Chunfeng Qu, Zhiyuan Wu, Feifei Wang, Xing-Ning Li, Ruochan Zhang, Chentong Xiao, Yuliang Ran   +10 more
doaj   +1 more source

Yeast Gcn2 retains activity following humanization of its auto‐phosphorylation region

FEBS Open Bio, EarlyView.
Using Saccharomyces cerevisiae as a model to study Gcn2 activation and regulation is limited by the lack of antibodies detecting phosphorylated Gcn2. To overcome this, we engineered Gcn2‐HsC, a yeast Gcn2 variant recognizable by commercial anti‐human phospho‐GCN2 antibodies.
Reuben A. Anderson, Anja H. Schiemann, Evelyn Sattlegger   +2 more
wiley   +1 more source

CAR-T manufacturing intensification: the next wave of CAR-T commercialization

Cell and Gene Therapy Insights
Since the commercialization of the first CAR-T therapies, these revolutionary treatments have reshaped the landscape of cancer therapy, offering unprecedented hope to patients with hematologic malignancies. Here, a panel of industry and healthcare sector experts to discuss the critical intersection of commercialization strategies and manufacturing ...
Alexey Bersenev, Emilie Kleiren, John Knighton, Paul Bowles   +3 more
openaire   +1 more source